Welcome to our dedicated page for Mustang Bio news (Ticker: MBIO), a resource for investors and traders seeking the latest updates and insights on Mustang Bio stock.
Mustang Bio, Inc. develops clinical-stage cell therapies for difficult-to-treat cancers, with programs centered on CAR T approaches and related oncology technologies. Company updates commonly cover MB-101, an IL13Rα2-targeted CAR T-cell therapy for astrocytomas and glioblastoma, MB-108, an HSV-1 oncolytic virus program, and the combination therapy MB-109.
Recurring news also includes FDA orphan drug designation activity, clinical and preclinical program disclosures, public offerings and warrants, reverse stock split actions, Nasdaq Capital Market listing compliance, and facility or asset changes tied to the company’s operating footprint.
Mustang Bio (Nasdaq: MBIO), a clinical-stage biopharmaceutical company, has closed a registered direct offering priced at-the-market under Nasdaq rules, raising $2.5 million through the sale of 6,130,000 shares at $0.41 per share. Concurrently, the company issued unregistered warrants for an additional 6,130,000 shares with the same exercise price, expiring five years from stockholder approval. The net proceeds will support working capital and general corporate purposes. H.C. Wainwright & Co. acted as the exclusive placement agent.
Mustang Bio (Nasdaq: MBIO), a clinical-stage biopharmaceutical company, announced a $2.5 million registered direct offering. The company will issue approximately 6.13 million shares at $0.41 per share. Unregistered warrants for the same amount of shares will be issued in a concurrent private placement. The offering is expected to close on June 21, 2024, pending customary conditions. H.C. Wainwright & Co. is the exclusive placement agent. Mustang plans to use the net proceeds for working capital and general corporate purposes.
Mustang Bio has announced positive efficacy and safety data from the Phase 1/2 clinical trial of MB-106, a CD20-targeted autologous CAR-T therapy, for Waldenstrom macroglobulinemia (WM). The trial demonstrated a 90% overall response rate among heavily pretreated patients, with durable responses noted, including one patient in complete remission for 31 months.
Outpatient administration was feasible, and no grade 3 or 4 CRS or severe neurotoxicity was observed. These results were presented at the European Hematology Association 2024 Hybrid Congress. Mustang Bio is developing MB-106 in collaboration with Fred Hutch Cancer Center and aims to advance the program further, contingent on acquiring additional funding or strategic partnerships.
Mustang Bio, Inc. announced the closing of a public offering, generating approximately $4 million in gross proceeds from the sale of common stock and warrants. The Company plans to use the funds for working capital and general corporate purposes. If all warrants are cash-exercised, potential additional gross proceeds of $12 million can be realized. The offering was facilitated by H.C. Wainwright & Co., with the securities offered under a registration statement on Form S-1 filed with the SEC.
Mustang Bio, Inc. announced a public offering of 16,877,638 shares of common stock, along with warrants, at a combined price of $0.237 per share to raise approximately $4 million. The offering is expected to close on May 2, 2024, with H.C. Wainwright & Co. as the placement agent. The proceeds will be used for working capital and general corporate purposes.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.